Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250009/S001

SQUID Liquid Embolic Agent (LEA)

Balt USA, LLC · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP250009/S001

What did the FDA approve?

The FDA record for P250009/S001, dated 2026-10-16, shows approval of the protocol for the COSMIC post-approval study, submitted under the normal 180-day track with no user fee. The supplement reason is listed as Postapproval Study Protocol, tied to the SQUID Liquid Embolic Agent (LEA), product code SGU, in neurology, submitted by Balt USA, LLC. The record does not describe the protocol's design, endpoints, sample size, or the conditions it addresses.

The source statement indicates the protocol was submitted to comply with conditions of approval in the original P250009 order. That wording is the agency's reported purpose, not independent evidence of safety or clinical effectiveness. The record does not show a change to the device's indications or labeling, and the six-character identifier alone does not confirm the original approval date or the full scope of the parent PMA. The decision applies to the PAS protocol, not a new approval of the whole system.

FDA approval order statement

Approval of the protocol for the COSMIC post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250009.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Neurology
Decision date
Oct 16, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250009/S001
Regulatory pathway
PMA supplement
Applicant
Balt USA, LLC
Product code
SGU
Decision code
APPR
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Neurovascular Liquid Embolic Agent.

Applicant
Balt USA, LLC
Product code
SGU
FDA device class
3

For the original device and its historical approval scope, see PMA P250009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250009 · Original PMA

    SQUID Liquid Embolic Agent (LEA)

  2. P250009/S001 received

    Application receipt date recorded by FDA.

  3. P250009/S002 · Related supplement

    SQUID Liquid Embolic Agent (LEA)

  4. P250009/S001 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250009

Product / regulatory recordCompanyPathwayDecision dateSource
Balt USA, LLCPMA approvalJan 30, 2026FDA
Balt USA, LLCPMA supplementSep 9, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Balt USA, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
29 Parker, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records